{"id":826933,"date":"2025-03-18T08:51:04","date_gmt":"2025-03-18T12:51:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\/"},"modified":"2025-03-18T08:51:04","modified_gmt":"2025-03-18T12:51:04","slug":"acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\/","title":{"rendered":"Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer\u2019s"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEW YORK, March  18, 2025  (GLOBE NEWSWIRE) &#8212; Today&#8217;s Marketplace (TMP) is proud to announce a featured interview with <strong>Acumen Pharmaceuticals<\/strong><strong>(NASDAQ: ABOS)<\/strong> CEO <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M4kVRPgcr0XT46T3XmR_YnJn8ZAu4S8oLmkuF32ybaxrOh_qtbVExOpDUqCdQIUAoChMJUpkzDG5oNcbZkbQsRwzLPHlPhO63FQeFkShZtU29dJmqkCnkMmCWKRMl6Pr\" rel=\"nofollow\" target=\"_blank\">Daniel O<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=a5z310xIV3YpklhnNYvjl-UO6rWwJ4ICnEsmaU0GBxwCWo26kaRaLwJV1Rzwejuac_Kob-BX3XsDGxYQrkgEK3bgTiZZ7Z0ECW8zI8cbiD63jhrC77ku44c3qVriDhge\" rel=\"nofollow\" target=\"_blank\"><u>\u2019<\/u><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j31egODLdB51-nJUPCt_4trPtXf9b_J6XSx-IgQpg5JkHtNuiDzX2z74kYZnHWjOnovf4pbUSVP57WLunmNLfPIOYaBP3xHQ3YOhgU-14weoyiOLxWTo4CCyGzVuVS_z\" rel=\"nofollow\" target=\"_blank\">Connell<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NGMV2-zt9R-A38IikvQfP2OVkGm_6XTFovap7tQqAfmS-X6-E2ips45nJ4arPH3DRrnAjtqdpqUMKZGVks4TDLPJGptcKbHc8382lyk-TdgWlhoMHqFJmwz5EzvMNLTyQDFQLQdT7DkyDIxEcPbp0g==\" rel=\"nofollow\" target=\"_blank\">Jessica Clark, DNP, RN<\/a>, Dean of the College of Nursing at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=q_ToHTzLkxH6rtNSl74da0aWjPP3YaCz3CYWfjLmbxNuif4haEYlLGMusl-1OVG-WxGT21kz5d_nImP_Cny8I0bOKH04ErYOZfgWcp966nuRe-Wg8kItoDkmoSYrMokc\" rel=\"nofollow\" target=\"_blank\">Creighton University<\/a>. The pair joined Today\u2019s Marketplace host Elizabeth Hart to discuss Alzheimer\u2019s Disease.<\/p>\n<p align=\"left\">The full interview <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rvRvQyEbPW8AdQLGASm1iZDE-w3kSnitgx_3pmUdGKY_fcqG71h3Ke2PFa58-64nFgtP_AYD8A-11egK09XgG2K2CbFCrmlHE_Pf1BYaax532TkgBwz0DrZV9me6bxnxJo_VgthtxGQFUExYkxxbq8iXhfC39ZzZzTA9BGLY3PL3YrfHbAyaVGNpsaWP_V4ShZJ0o2i-t_H7Y9RXblFIoxBFIrzFNLpm3YQ2tYDQmJVs6nLCLkFX6R52nx_NeAUPP4Xj6tepMUsiR3-yojpn7uN3aug6uq50XP2dMOvtdxI21NDyNgVdVbZT4oiedZM2nX6WqSegn1ZaLzJ0tjZzfUhFn3WvdjPg7sz-AP9v_KQ=\" rel=\"nofollow\" target=\"_blank\">can be viewed online here.<\/a><\/p>\n<p align=\"left\">\u201cIn the U.S., we have over six million people diagnosed with active Alzheimer\u2019s today, and worldwide, about 55 million,\u201d said Clark.<\/p>\n<p align=\"left\">Dr. Clark went on to say that the economic impact of this devastating disease could seem \u201cinsurmountable at times,\u201d explaining that the treatment and long-term care costs associated with Alzheimer&#8217;s are about $360 billion dollars. And that does not even consider the time investment and productivity losses experienced by caregivers.<\/p>\n<p align=\"left\">Mr. O\u2019Connell then explained that his company, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4l6VyojnhUGXyjYrnGqsOgyXMoevKMW_P66SK89d-uie0SfLpCjdqraFjMsBn2vcMTtbrF5SVYDWHsqB5bxPt5vIjTJpfwJGBhAehI2og5E=\" rel=\"nofollow\" target=\"_blank\">Acumen Pharmaceuticals<\/a>, is singularly focused on targeted Alzheimer\u2019s therapies. \u201cAcumen is focused on developing therapeutics for people living with Alzheimer&#8217;s disease. We are advancing sabirnetug, which is a monoclonal antibody that was designed to target amyloid beta oligomers (A\u03b2Os), [a specific contributing factor in the disease.]\u201d<\/p>\n<p align=\"left\">He continued to point out that the drug had positive results in their Phase I study, which indicated that sabirnetug had a good safety profile and showed the anticipated pharmacological effects on the A\u03b2Os targets in a short-term study.<\/p>\n<p align=\"left\">\u201cWe are now advancing it to a sizable Phase II study involving [approximately] 540 patients in the U.S., North America, and Europe, and are excited to complete enrollment for that study in the first half of this year.\u201d<\/p>\n<p align=\"left\">TMP\u2019s interviews cover important business topics and solutions with insights from academic experts and business leaders.<\/p>\n<p align=\"left\">\u201cConversations like these are critically important, and I\u2019m pleased to join Today\u2019s Marketplace to discuss the advancements reshaping the treatment of Alzheimer\u2019s disease,\u201d said Mr. O\u2019Connell. \u201cAt Acumen, we\u2019re working on a potential next-generation treatment to help address the massive unmet need in this disease.\u201d<\/p>\n<p align=\"left\">\u201cStaying informed about emerging pharmaceuticals is vital for both patient care and understanding how individuals can reshape business models and future healthcare delivery. By tuning into Today&#8217;s Marketplace, healthcare consumers gain insights into future treatments and efficient care, while healthcare providers gain knowledge to improve patient outcomes, streamline clinical operations, and deliver more effective, accessible care.\u201d &#8211; Dr. Jessica Clark, DNP RN<\/p>\n<p align=\"left\">\n        <strong>About Acumen Pharmaceuticals <\/strong>\n      <\/p>\n<p align=\"left\">Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (A\u03b2Os) for the treatment of Alzheimer\u2019s disease (AD). Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble A\u03b2Os, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer\u2019s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bsqWTsB6rwRjvhaws2n3ejjM42MSqQRX0xO7edMK9-R219Vnc-pqOFLd2f0DVR-hzEdJOS0vlavx7EtFudAplhCDx7CQI0LJq1o-42ZnsjQ=\" rel=\"nofollow\" target=\"_blank\">acumenpharm.com<\/a>.<\/p>\n<p align=\"left\">\n        <strong>About Creighton University<\/strong>\n      <\/p>\n<p align=\"left\">Creighton University is a Jesuit, Catholic university located in Omaha, Neb., that enrolls more than 4,100 undergraduate and 3,200 professional school and graduate students bridging health, law, business, and the arts and sciences for a more just world. For more information, visit our website at: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=c267j0sUbUWJCCgZV9ieLjr7gVTY6HY_hmuWZwmDVNGav1w-DXRzb1ebbhbMu0eHPTO-WejgW1u3s2rNHXTaKfyiAC44tCpniQBu24nSQPA=\" rel=\"nofollow\" target=\"_blank\">www.creighton.edu.<\/a><\/p>\n<p align=\"left\">\n        <strong>About Today&#8217;s Marketplace\u00a0<\/strong>\n      <\/p>\n<p align=\"left\">Today&#8217;s Marketplace (TMP) is a series of C-Suite interviews filmed at the prestigious New York Stock Exchange (NYSE) and the NASDAQ MarketSite studio for earned media distribution. TMP&#8217;s multi-channel distribution provides robust, authoritative, and credible media exposure to under-reported stories. Visit TMP at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_sD6aOBhLylIOu7lu7VUtsDT-_6AZaPhOsFknlfY2GSufZ3CDGfjLTKCK3ehwowjLbQ5pvNasc8wSni2hKSlqM0HWkQpF4EWvFNn9Upvvrg=\" rel=\"nofollow\" target=\"_blank\">todaysmarketplace.tv<\/a>.<\/p>\n<p align=\"left\">For More Information Contact:<br \/>Today\u2019s Marketplace<br \/>Dian Rygh, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dy4JrG-P4grRGxIgzOce-1GO8rKRmkqHK_zTKcMeWFICNMyTYlnle2KpZ45ik0ox2RJPOjj6s8iRrgmEfb-IvYcMtfNpRMLIgEWiLi4rDQ0=\" rel=\"nofollow\" target=\"_blank\">producers@cmghd.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTkwNyM2ODEwMjM3IzUwMDExOTY0Nw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MmVlMDQzY2QtOTU5Yy00YTI3LTlmMzktZjFmYzBhZGI0NmQzLTUwMDExOTY0Ny0yMDI1LTAzLTE4LWVu\/tiny\/Today-s-Marketplace.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) &#8212; Today&#8217;s Marketplace (TMP) is proud to announce a featured interview with Acumen Pharmaceuticals(NASDAQ: ABOS) CEO Daniel O\u2019Connell and Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The pair joined Today\u2019s Marketplace host Elizabeth Hart to discuss Alzheimer\u2019s Disease. The full interview can be viewed online here. \u201cIn the U.S., we have over six million people diagnosed with active Alzheimer\u2019s today, and worldwide, about 55 million,\u201d said Clark. Dr. Clark went on to say that the economic impact of this devastating disease could seem \u201cinsurmountable at times,\u201d explaining that the treatment and long-term care costs associated with Alzheimer&#8217;s are about $360 billion dollars. And that does not even &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer\u2019s&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-826933","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer\u2019s - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer\u2019s - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) &#8212; Today&#8217;s Marketplace (TMP) is proud to announce a featured interview with Acumen Pharmaceuticals(NASDAQ: ABOS) CEO Daniel O\u2019Connell and Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The pair joined Today\u2019s Marketplace host Elizabeth Hart to discuss Alzheimer\u2019s Disease. The full interview can be viewed online here. \u201cIn the U.S., we have over six million people diagnosed with active Alzheimer\u2019s today, and worldwide, about 55 million,\u201d said Clark. Dr. Clark went on to say that the economic impact of this devastating disease could seem \u201cinsurmountable at times,\u201d explaining that the treatment and long-term care costs associated with Alzheimer&#8217;s are about $360 billion dollars. And that does not even &hellip; Continue reading &quot;Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer\u2019s&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-18T12:51:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTkwNyM2ODEwMjM3IzUwMDExOTY0Nw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer\u2019s\",\"datePublished\":\"2025-03-18T12:51:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\\\/\"},\"wordCount\":603,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTkwNyM2ODEwMjM3IzUwMDExOTY0Nw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\\\/\",\"name\":\"Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer\u2019s - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTkwNyM2ODEwMjM3IzUwMDExOTY0Nw==\",\"datePublished\":\"2025-03-18T12:51:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTkwNyM2ODEwMjM3IzUwMDExOTY0Nw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTkwNyM2ODEwMjM3IzUwMDExOTY0Nw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer\u2019s\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer\u2019s - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\/","og_locale":"en_US","og_type":"article","og_title":"Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer\u2019s - Market Newsdesk","og_description":"NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) &#8212; Today&#8217;s Marketplace (TMP) is proud to announce a featured interview with Acumen Pharmaceuticals(NASDAQ: ABOS) CEO Daniel O\u2019Connell and Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The pair joined Today\u2019s Marketplace host Elizabeth Hart to discuss Alzheimer\u2019s Disease. The full interview can be viewed online here. \u201cIn the U.S., we have over six million people diagnosed with active Alzheimer\u2019s today, and worldwide, about 55 million,\u201d said Clark. Dr. Clark went on to say that the economic impact of this devastating disease could seem \u201cinsurmountable at times,\u201d explaining that the treatment and long-term care costs associated with Alzheimer&#8217;s are about $360 billion dollars. And that does not even &hellip; Continue reading \"Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer\u2019s\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-18T12:51:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTkwNyM2ODEwMjM3IzUwMDExOTY0Nw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer\u2019s","datePublished":"2025-03-18T12:51:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\/"},"wordCount":603,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTkwNyM2ODEwMjM3IzUwMDExOTY0Nw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\/","name":"Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer\u2019s - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTkwNyM2ODEwMjM3IzUwMDExOTY0Nw==","datePublished":"2025-03-18T12:51:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTkwNyM2ODEwMjM3IzUwMDExOTY0Nw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTkwNyM2ODEwMjM3IzUwMDExOTY0Nw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acumen-pharmaceuticals-ceo-discusses-novel-targeted-therapies-for-alzheimers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer\u2019s"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/826933","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=826933"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/826933\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=826933"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=826933"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=826933"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}